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Abstract: Facial rejuvenation is a significant process involved in restoring youthfulness. The 
introduction of less invasive procedures has increased acceptance of such procedures. Often a 
combination of different techniques allows individualized treatment with optimal outcomes. 
Furthermore, this leads to a natural look without a significant downtime. We report herein the 
use of such a combined approach in middle-aged women with particular emphasis on botulinum 
toxin type A, dermal fillers, and chemical peels.
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In the past the concept of facial rejuvenation was dominated by invasive surgical pro-
cedures, in particular different techniques of partial and full face lift. Nowadays there 
is a clear tendency for less invasive procedures which are quicker and simpler and that 
do not divert patients from their daily routine and activities for prolonged periods. 
They can provide effective, safe, relatively long-lasting, and natural results.1,2
With the development of new technologies and techniques, greater knowledge of 
tissue anatomy and physiology, stem cells, lasers and other energy sources, new fillers, 
and the ever more versatile use of botulinum toxin type A (BTX-A), a new perspective 
in cervicofacial rejuvenation treatments has been established. In the following we will 
describe our practice and experiences. We believe that needs for rejuvenation and the 
appropriate choice of the medical armamentarium are age- and gender-dependent so 
we focused on women aged 30 to 50 years.3
Etiological factors related to skin aging
The aging process is related to intrinsic and extrinsic factors. The main frequent changes 
observed among women aged between 30 and 60 years due to the natural and continuing 
aging process are the appearance of small wrinkles, atrophy of subcutaneous fat, and 
decreases in collagen and elastin production. There is also an evident decrease in the 
turnover of skin cells. Gravidity and muscular aging are involved in more evident folds, 
increasing skin flaccidity. Repeated contractions of the mimic muscles might be involved 
in the process. In young participants an magnetic resonance imaging (MRI) study was 
used to demonstrate that the anterior convexity curve of the mimic muscles is due to the 
existence of a deep fat pad at the back of these muscles. While this mass of fat is effec-
tively a mechanical sliding plane, its convexity constitutes the founding principle of a 
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due to the repeated contractions that expel the underlying fat and 
increase the tonus at rest. The structural aging becomes visible 
and, with time, the person’s expression consequently becomes 
more rigid.2 The skin becomes drier and thinner and there is 
an evident loss in the skin texture and elasticity. A variety of 
external or extrinsic factors often act together with the aging 
process to prematurely age the skin. The most important and 
aggressive extrinsic factor related to aging is caused by sun 
exposure (photoaging). Other external factors include repeti-
tive or exaggerated mimic expressions, gravity, sleeping posi-
tion, and smoking. The combination of extrinsic and intrinsic 
aging factors determine different aspects and characteristics in 
patients aged under 50 years. The most frequent are skin and 
deep structure flaccidity, wrinkle expression in the upper third of 
the face, tear through, increase in the nasolabial fold, drop of the 
angle of the mouth, loss of definition in the mandibular border, 
cervico-facial platysmal bands, changes in skin pigmentation, 
and evident veins (or telangiectasia).1
Since symmetry is one of the major biologic factors 
contributing to facial attractiveness, facial rejuvenation pro-
cedures are commonly aimed at improving symmetry. There 
is a need for adapting and specifying esthetic approaches to 
the special needs of the individual patient.
We will now discuss three minimally invasive proce-
dures; smoothing wrinkles and folds by temporary chemod-
enervation of facial muscles with botulinum toxin, correction 
of volume loss by fillers, and improvement of skin surface 
and dyschromia by peels.
Botulinum toxin type A (BTX-A)
BTX-A is produced by Clostridium botulinum. Synthesized 
as a single-chain polypeptide of ∼150 kDa, BTX has rela-
tively little potency until it is cleaved by trypsin or bacterial 
enzymes into two chains, a heavy chain of 100 kDa respon-
sible for binding to the target structure and a light chain of 
50 kDa known as the toxifying chain. These two chains are 
linked together by a disulfide bond. The light chain contains 
a Zn2+-binding motif with enzymatic activity. BTX-A is a 
zinc-dependent endopeptidase.
When BTX is injected into a muscle, the heavy chain of 
the molecule binds to glycoproteins expressed specifically on 
cholinergic nerve endings. After internalization of the whole 
molecule by pinocytosis, the chains are cleaved within the cyto-
plasm. The light chain binds with high specificity to the soluble 
N-ethylmaleimide-sensitive fusion (SNARE) attachment pro-
tein receptors essential for exocytosis of acetylcholine. BTX-A 
cleaves plasma membrane synaptosome associated protein 
[SNAP-25] that results in a blockade of vesicle fusion.4,5
Two to five days after BTX is injected into a muscle 
paresis occurs which lasts for at least three months and 
  gradually starts to wear off. The subjective duration of action 
in a given patient seems to be stable, but there is a great 
variability between different people. Dose-effect correla-
tions are known for electromyographic activity. Even very 
low doses produce some effect. By increasing the doses 
a plateau is reached where further dose increases will not 
result in stronger effects. Dose-duration correlations exist to 
a lesser extent. Saturation will be seen with higher dosages 
after approximately three months.5
On the European Market, three different branches 
of BTX-A are officially registered: Botox®/Vistabel® 
(Allergan), Dysport® (Ipsen)/Azzalure® (Galderma), and 
Xeomin®/Bocouture® (Merz). The units are not directly 
comparable. The products have different amounts of 
complexing proteins or are free of complexing proteins 
(ie, Xeomin®/Bocouture®).6 The diffusion of the different 
drugs seems to be dependent on concentration.7 BTX-A 
has an excellent safety profile8 and has been used exten-
sively for facial rejuvenation with a focus on hyperki-
netic wrinkles and to improve facial wound healing after 
surgery.9–12
Fillers
Fillers can be permanent or temporary. Different products 
can be inserted under the skin in different layers to correct 
depressed folds, wrinkles, furrows, scars, angles, and flac-
cidity. The main concept is to create a volume or even to 
replace an original volume compromise for the aging process 
of the face and neck.
The types and number of dermal fillers have evolved, 
allowing clinicians to select the most appropriate agent for 
each specific purpose. Filler properties differ both between 
and among classes, so clinicians must have a thorough 
understanding of these properties and the best techniques to 
use to provide the most satisfactory outcomes.
Fillers can be divided into permanent and temporary 
categories. The latter are metabolized by the human body. 
Permanent fillers are no longer recommended because their 
long term safety has not been established. Nevertheless, 
some authors have published excellent results for the use of 
permanent fillers like ArteFill®.13
Temporary fillers consist of various substances includ-
ing collagen, hyaluronic acid (HA), alginates, and other 
polysaccharides. Substances such as polylactic acid or 
hydroxylapatite are considered to be semipermanent fillers 
with a longer half life.14Clinical Interventions in Aging 2010:5 submit your manuscript | www.dovepress.com
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The most common used substance today is HA, a   natural 
polysaccharide and a component of human dermis and epi-
dermis. HA-based fillers offer excellent biocompatibility 
while providing the same structural and mechanical prop-
erties of normal subcutaneous tissue. Naturally occurring 
hyaluronan is rapidly broken down by hyaluronidase with 
a half-life of about 12 hours and eliminated through the 
lymphatics and by the hepatic metabolism to carbon dioxide 
and water.14,15 Cross-linking gives HA fillers an in vivo life 
span of 6 to 18 months. The use of HA is particularly attrac-
tive for soft-tissue augmentation, because it is hydrophilic 
and a normal extracellular component of skin. It is directly 
involved in extracellular matrix function and because of 
its tolerability profile, it can be used without skin testing.15 
Corrections of displacement can easily be done by injection 
of hyaluronidase.16
Factors that impact HA persistence include HA concen-
tration, percentage of cross-linkage, type of cross-linkage, 
water binding capacity, and injection technique. Monophasic 
gels seem to be more stable compared with diphasic gels. 
To improve longevity, manufacturers use various agents 
to cross-link the HA. As a result, the final proportion of 
cross-linked HA and the degree of cross-linking impact the 
physical characteristic of the final product. The water-binding 
capacity – or hydrophilic nature – allows the HA to create 
larger volumes relative to their mass. Recent study results sug-
gest that increased concentrations of HA prolong persistence. 
If all other factors are the same among HAs, the product 
with the highest degree of cross-linking experiences the least 
amount of degradation by enzymes and free radicals. The 
cross-linking agents also have an impact on connective tissue 
reaction to injectable fillers.17 Injection technique can play a 
role in longevity of the dermal filler. Injection into the deep 
dermis has been shown to increase de novo collagen synthesis, 
hypothesized to be the result of fibroblast stretching. There-
fore as the HA is degraded, novel collagen synthesis replaces 
the HA which results in longer-lasting correction. Semi-
permanent fillers often cause more pain during injection. 
Nerve blocks are used to reduce this during the procedure.18 
The combination of HA filler with BTX-A has been shown 
to produce improved and longer lasting effects for glabellar 
lines than either BTX-A or filler alone.19
Another filler with potential long term effects is autolo-
gous adipose tissue used for facial sculpturing. Adipose 
tissue is believed to constitute an ideal source of uncultured 
stromal stem cells. By optimizing the harvesting, storage, 
and transplantation of adipose tissue, long-lasting results 
can be obtained.20 The long lasting volumizing in many 
patients seems to be due to mesenchymal stem cells that 
eventually differentiate into fibroblasts, adipocytes, and blood 
vessel.21–23 Autologous fat transfer has been successfully used 
for facial lipodystrophy and for facial sculpturing in esthetic 
facial surgery.24,25 Autologous fat transfer to the midface has 
definite long-term volume augmentation results. On aver-
age, approximately 32% of the injected volume remains at 
16 months. However, some variability exists in the percentage 
of volume that remains, meaning that a touch-up procedure 
may be required.26
In the future is it hoped that better identification of and 
enrichment with stem cells for adipose transfer will create a 
more predictable long-term outcome.27 Progenitor, endothe-
lial, and mesenchymal stem cells derived from adipose tissue 
could therefore not only be central to plastic and reconstruc-
tive surgery applications, but also become the focus of an 
array of therapeutic solutions for many disease conditions, 
such as those affecting bone, cartilage, muscle, liver, kidney, 
the heart, the brain, and the pancreas, expanding the possible 
indications and translational potential of tissue, cell-based, 
and regenerative medicine strategies.21
Chemical peeling
Chemical peeling is the topical application of chemical 
agents to the skin, which causes controlled destruction of 
part of or the entire epidermis, with or without the dermis, 
leading to exfoliation and removal of superficial lesions, 
followed by regeneration of new epidermal and dermal tis-
sues. Indications for chemical peeling include pigmentary 
disorders, superficial acne scars, aging skin changes, and 
benign epidermal growths. Peels have been classified accord-
ing to the chemical compounds involved or the depth of the 
exfoliation.28
Superficial chemical peels are currently performed 
with various compounds including trichloracetic acid, 
alpha hydroxy acids, and Jessner’s solution (14% lactic acid, 
14% resorcinol, and 14% salicylic acid). Alpha hydroxy 
acids, in particular glycolic acid (GA), are common chemi-
cal peel agents. GA peels in concentration ranging from 
20%–70% have been shown to be effective in reducing facial 
hyperpigmentation and fine lines/wrinkles.29
Based on the available information, these salicylic 
ingredients are safe for use when formulated to avoid skin 
irritation or to avoid increasing the skin’s sun sensitivity, or, 
when increased sun sensitivity would be expected, directions 
for use include the daily use of sun protection.30,31
Kligman and Kligman have developed salicylic acid, a 
beta hydroxy acid (30% in a hydro ethanolic vehicle), as an Clinical Interventions in Aging 2010:5 submit your manuscript | www.dovepress.com
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alternative peel to GA.32 The benefits of salicylic acid peels 
are resurfacing moderately photodamaged facial skin, fading 
of pigment spots, decreased surface roughness, and reduction 
of fine lines also in pigmented skin.33
Derivatives of salicylic acid, especially long-chain fatty 
acylconjugates of salicylic acid, have been claimed to be 
more effective at lower concentrations for skin peeling use. 
A lipophilized ester-derivative of salicylic acid, capryloyl 
salicylic acid (CSA), has been shown to be an effective exfo-
liating agent due to its reduced penetration in the skin.34
Salicylic acid causes a loss of cornified cells from the 
horny layer followed by the activation of the epidermal 
basal cells and the underlying fibroblasts.35 In photoexposed 
human facial skin, immature cornified envelopes (CEs) were 
replaced with mature CEs four weeks after treatment with 
salicylic-polyethylene glycol (PEG). Restoration of photo-
damaged stratum corneum by this treatment involved the 
normalization of keratinocyte differentiation.36
Our concept of minimally invasive 
facial rejuvenation in women 
between 30 and 50 years of age
There is no doubt that that classic surgical and nonsurgical 
procedures such as blepharoplasty, rhytidoplasty, or laser 
peelings still represent important techniques in esthetic and 
facial rejuvenation. It is also obvious that the combination 
of these traditional treatments with other procedures that 
offer improved skin quality and texture, wrinkles, low risk, 
good cost-effectiveness, low morbidity, and quick recovery 
represent an important advance and a real tendency. In this 
context, BTX-A injection combined with different types of 
fillers or soft tissue augmentation represent an important non-
surgical resource that, combined with traditional techniques, 
can improve or extend the results.
These two procedures, BTX and fillers, can also be com-
bined with some kinds of lasers or light sources in order to pro-
duce a nonablative or fractional skin rejuvenation, superficial 
improvement, pigmented lesions, vascular alterations, wrinkles, 
and acne scars as well as to offer adequate skin tightening. The 
concept is to treat the wrinkles and folds and also improve the 
photodamage related to the aging process and skin laxity.
This report is based on extensive experience with com-
bined procedures in facial rejuvenation. We will focus on 
the period of time from July 1996 to June 2010. A total of 
1,559 patients (91% female) have been treated, aged under 
50 years. Middle-aged women are a major group for esthetic 
treatments. Fifty point three percent of patients received a 
combined treatment. The major combination was BTX-A 
and fillers (n = 784, with 97% females). The main treated 
areas were periorbital, frontal, glabellar, platysma, depressor 
anguli oris, and nasal (Figures 1–7). Eighty-four percent of 
these patients received a reinjection of BTX-A on average 
five months after the first treatment. This high number indi-
cates patients’ satisfaction leading to a continuation of the 
initial procedures despite costs.
Facial plastic surgery procedures, such as cervicofacial 
rhytidoplasty or blepharoplasty, are the most common proce-
dures used in combination with BTX-A and fillers. Whether 
the optimal moment for injecting BTX-A is before or after 
the surgery remains a subject of debate. A potential advantage 
of using it prior to surgical intervention is the stabilization of 
cutaneous or even myocutaneous tissues. This, in turn, would 
facilitate their adequate accommodation, decreasing tension 
in the incision, suture, flaps and traction areas, thus improving 
the quality of the cicatricial process. Despite its transient dura-
tion and relatively high cost limit the use of neurotoxins as an 
adjunctive agent in surgery is suitable for most patients. In the 
first weeks following surgery, the relaxing effect of BTX-A is 
disguised by tissue edema. Thus, its useful life and cosmetic 
results and effects are considerably shortened. The versatil-
ity and reproductive effect of BTX-A among these patients 
represent an important characteristic of this approach.
The aspect of a frontal surgical surgery (open or video-
assisted) can be temporarily mimicked or reproduced with an 
AB
Figures  1A  and  1B  A  60  year-old  patient  after  hyaluronic  acid  injection  in 
nasolabial fold, malar region, and mouth commissure (1.6 mL) and Intense Pulsed 
Light rejuvenation. Result 2 months after HA injection and two sessions of IPL and 
Nd:YAG laser (Restylane, Perlane, and Photosilk Plus and Synchro – Deka, Italy).
AB
Figures 2A and 2B A 53-year-old female patient treated with 1.8 mL of HA 
( Juvederm) in the mandibular border, malar region, mouth commissure (marionette 
lines), and nasolabial fold.Clinical Interventions in Aging 2010:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
297
Facial rejuvenation for middle-aged women
adequate application into the frontal, corrugators, procerus, 
and orbicularis oculi muscles. This resource is useful for 
patients aged under 50 years, who do not want or do not 
have clinical conditions to undergo surgery or prefer a less 
invasive procedure. BTX-A application can effectively offer 
an elevation of the lateral aspect of the eyebrow or of the 
mouth commissure. Thus, for the treatment of eyelid ptosis, 
whatever technique is used (open, endoscopic, or combined 
approach), previous neurotoxin application may be very 
useful for inhibiting or smoothing possible cutaneous and 
muscular creases in the treated areas. On the upper third of 
the face, BTX-A can attenuate the hyperdynamic wrinkles 
caused by muscular activity, eliminating the need for either a 
coronal incision in treating the frontal musculature or for an 
endoscopic procedure. When it is injected into the palpebral 
region, it is possible to obtain an elevation of the caudal por-
tion of the eyebrow and modify its shape or position, which 
is useful especially when performing a blepharoplasty. This 
palpebral elevation (lifting effect) brings about significant 
appearance of rejuvenation as well as the improvement of 
“crow’s feet”. By using this combination, it is possible, in 
selected cases, to decrease the quantity of skin to be removed 
and consequently, to decrease the scar dimension. Although 
many researchers promote its postoperative use, there is no 
consensus as to the ideal time of application in these cases.
BTX-A injection into the lateral and anterior cervi-
cal regions and in the depressor anguli oris is capable of 
attenuating the platysmal band and elevating the angles of 
the mouth, creating harmony between this area and the rest 
of the face and improving the result of the rhytidoplasty. 
Although BTX-A can be used in combination with fillers, 
lasers, and surgical procedures or even applied into other 
areas of the face and neck, we should use common sense 
and carefully examine the patient’s anatomy when using this 
neurotoxin in order to avoid excessive muscle relaxation, 
muscle paralysis, or the end result of a face incapable of 
natural expressions.
Combination with peels
Several fillers, skin care techniques, chemical peelings, 
dermabrasion, and different types of ablative and nonablative 
lasers and energy sources can be combined with BTX-A use 
in order to prevent or to treat the aging process. To improve 
superficial skin texture and pigmentary problems chemical 
peels have been used successfully.
B A
Figure 4 A 48-year-old woman. BTX-A in the upper third of the face. HA filler 
for mouth commisure, vermillion, malar region, and mandibular border (1.6 ml); 
A) before and B) after the procedure.
B A
Figure 5 A 52-year-old woman. A) Before and B) after full face trichloracetic acid 
(TCA) peel, BTX-A for the depressor anguli oris and the upper third of the face. 
1.2 ml of HA filler was injected in both the nasolabial fold and oral commissure.
B A
Figure 6 A 50-year-old woman. A) Before treatment and B) She was treated by a 
combination of HA filler in the vermillion, nasolabial folds, and oral commissure.
A
Figures 3A and 3B A 51-year-old patient. HA injections in the wrinkles around 
the mouth, mandibular border, malar region, mouth commissure, and nasolabial 
fold. Total volume injection was 1.9 mL.
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Twenty patients (15 females and 5 males, skin type I–IV) 
with acne, acne scars, or actinic damage were included in 
an open clinical trial. All of them underwent a preparation 
period of two weeks before first peeling with 5% CSA solu-
tion. The peeling was performed twice a month for a total of 
4 to 5 treatments. The concentration of CSA was increased 
to 10% by the second treatment. Patients’ global assessments 
and physicians’ global assessments of the CSA peels were 
considered good or better in its clinical effects in 18 of 18 
and 17 of 18 patients who completed the series of peels. 
Two patients dropped out because of intolerance to either 
the preparation agents or to 5% CSA. In all other patients 
the treatment was well tolerated without any serious adverse 
effects. All patients reported some tingling sensations and 
desquamation 24–48 hours after the procedure. There was no 
downtime from work. There is some evidence that smoking 
might negatively affect the efficacy of CSA peels. CSA peels 
are well tolerated in most patients of skin type I–IV with 
improvement of inflammatory acne lesions, facial acne scars, 
radiance, pigmentary changes, and fine wrinkling.37 Future 
researchers could investigate the performance of repeated 
series every other year.
Perspectives
Improved knowledge of cellular and skin aging, the use of 
stem cells, new and safer filler options, the technical evolution 
of surgical techniques, advances of laser sources, fractional 
laser and other energy sources, as well as new neurotoxin 
complexes represents a promising future in the treatment of 
the aging aspects of patients aged 30 to 50 years.
Conclusions
The appropriate evaluation and correct use of these 
minimally or less invasive techniques led to a younger and 
healthier look for the treatment of facial aging. BTX-A is 
one of the most commonly used nonsurgical techniques. 
This neurotoxin in conjuction with fillers has a low risk, 
efficiently treats skin aging, and also prevents or reduces 
some aspects and characteristics related to the facial aging 
process. Chemical peels like CSA can further contribute to 
a youthful facial appearance with a more even skin tone and 
increased radiance.
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